Communicating and understanding statistical measures when quantifying the between-group difference in competing risks

被引:3
作者
Wu, Hongji [1 ]
Zhang, Chengfeng [1 ]
Hou, Yawen [2 ]
Chen, Zheng [1 ]
机构
[1] Southern Med Univ, Sch Publ Hlth, Dept Biostat, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Peoples R China
[2] Jinan Univ, Sch Econ, Dept Stat & Data Sci, Guangzhou, Peoples R China
关键词
Competing risks; cause-specific hazard; subdistribution hazard; restricted mean time lost; clinical interpretation; MEAN SURVIVAL-TIME; LIFE-YEARS LOST; CUMULATIVE INCIDENCE; HAZARD RATIOS; MODEL; TRIAL; TESTS; SUBDISTRIBUTION; BIAS;
D O I
10.1093/ije/dyad127
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Competing risks issues are common in clinical trials and epidemiological studies for patients in follow-up who may experience a variety of possible outcomes. Under such competing risks, two hazard-based statistical methods, cause-specific hazard (CSH) and subdistribution hazard (SDH), are frequently used to assess treatment effects among groups. However, the outcomes of the CSH-based and SDH-based methods have a close connection with the proportional hazards (CSH or SDH) assumption and may have an non-intuitive interpretation. Recently, restricted mean time lost (RMTL) has been used as an alternative summary measure for analysing competing risks, due to its clinical interpretability and robustness to the proportional hazards assumption. Considering the above approaches, we summarize the differences between hazard-based and RMTL-based methods from the aspects of practical interpretation, proportional hazards model assumption and the selection of restricted time points, and propose corresponding suggestions for the analysis of between-group differences under competing risks. Moreover, an R package 'cRMTL' and corresponding step-by-step guidance are available to help users for applying these approaches.
引用
收藏
页码:1975 / 1983
页数:9
相关论文
共 49 条
[1]   Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy [J].
Alexander, Brian M. ;
Schoenfeld, Jonathan D. ;
Trippa, Lorenzo .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1158-1159
[2]   Decomposition of number of life years lost according to causes of death [J].
Andersen, P. K. .
STATISTICS IN MEDICINE, 2013, 32 (30) :5278-5285
[3]   Competing risks in epidemiology: possibilities and pitfalls [J].
Andersen, Per Kragh ;
Geskus, Ronald B. ;
de Witte, Theo ;
Putter, Hein .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2012, 41 (03) :861-870
[4]   Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement [J].
Austin, Peter C. ;
Fine, Jason P. .
STATISTICS IN MEDICINE, 2017, 36 (08) :1203-1209
[5]   Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].
Awada, Ahmad ;
Colomer, Ramon ;
Inoue, Kenichi ;
Bondarenko, Igor ;
Badwe, Rajendra A. ;
Demetriou, Georgia ;
Lee, Soo-Chin ;
Mehta, Ajay O. ;
Kim, Sung-Bae ;
Bachelot, Thomas ;
Goswami, Chanchal ;
Deo, Suryanarayan ;
Bose, Ron ;
Wong, Alvin ;
Xu, Feng ;
Yao, Bin ;
Bryce, Richard ;
Carey, Lisa A. .
JAMA ONCOLOGY, 2016, 2 (12) :1557-1564
[6]   Nonparametric tests for transition probabilities in nonhomogeneous Markov processes [J].
Bakoyannis, Giorgos .
JOURNAL OF NONPARAMETRIC STATISTICS, 2020, 32 (01) :131-156
[7]   Practical methods for competing risks data: A review [J].
Bakoyannis, Giorgos ;
Touloumi, Giota .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2012, 21 (03) :257-272
[8]   Hazard ratios in cancer clinical trials-a primer [J].
Blagoev, Krastan B. ;
Wilkerson, Julia ;
Fojo, Tito .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (03) :178-183
[9]   Estimation and modeling of the restricted mean time lost in the presence of competing risks [J].
Conner, Sarah C. ;
Trinquart, Ludovic .
STATISTICS IN MEDICINE, 2021, 40 (09) :2177-2196
[10]  
de Wreede LC, 2011, J STAT SOFTW, V38, P1